EBIT Margin: Earnings before interest and taxes as a portion of total revenues. Calculated as: EBIT / Total Revenues
CytomX Therapeutics, Inc. (CTMX) had EBIT Margin of -264.43% for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$5.96M |
|
$-14.23M |
|
-- |
|
$5.96M |
|
$21.73M |
|
$-15.77M |
|
$1.60M |
|
$-14.17M |
|
$-14.17M |
|
$-14.23M |
|
$-14.23M |
|
$-14.23M |
|
$-14.23M |
|
$-15.77M |
|
$-16.27M |
|
165.00M |
|
165.00M |
|
$-0.09 |
|
$-0.09 |
|
| Balance Sheet Financials | |
$149.22M |
|
$1.72M |
|
$9.04M |
|
$158.25M |
|
$41.03M |
|
-- |
|
$9.84M |
|
$50.87M |
|
$107.39M |
|
$105.97M |
|
$107.39M |
|
165.07M |
|
| Cash Flow Statement Financials | |
$-52.34M |
|
$-45.33M |
|
$93.80M |
|
$39.08M |
|
$35.21M |
|
$-3.87M |
|
$4.82M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.64 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-264.43% |
|
|
EBIT Margin |
-264.43% |
-- |
|
-237.65% |
|
-238.62% |
|
$-52.36M |
|
-- |
|
-- |
|
-- |
|
0.04 |
|
-- |
|
3.66 |
|
24.59 |
|
-13.25% |
|
-13.43% |
|
-8.99% |
|
-13.25% |
|
$0.65 |
|
$-0.32 |
|
$-0.32 |
|